CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients

CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients

BackgroundTacrolimus is an approved first-line immunosuppressive agent for kidney transplantations. Part of interindividual and interethnic differences in the response of patients to tacrolimus is attributed to polymorphisms at CYP3A5 metabolic enzyme. CYP3A5 gene expression status is associated wit...

Full description

Bibliographic Details
Main Authors: Effrosyni Mendrinou, Mohamed Elsayed Mashaly, Amir Mohamed Al Okily, Mohamed Elsayed Mohamed, Ayman Fathi Refaie, Essam Mahmoud Elsawy, Hazem Hamed Saleh, Hussein Sheashaa, George P. Patrinos
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Pharmacology
Subjects:
CYP3A5
kidney transplantation
living donor
tacrolimus
Egyptian population
dose requirements
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.01218/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2020.01218/full

Similar Items